Significance: Development of donor-specific antibodies (DSA) after kidney transplantation is associated with reduced allograft survival. A few strategies have been tested in controlled clinical trials for the treatment of antibody-mediated rejection (AMR), and no therapies are approved by regulatory authorities. Thus development of antihumoral therapies that provide prompt elimination of DSA and improve allograft survival is an important goal. Recent Advances: Proteasome inhibitor (PI)-based regimens provide a promising new approach for treating AMR. To date, experiences have been limited to off-label bortezomib use in AMR. Key findings with PI-based therapy are that they provide effective primary and rescue therapy for AMR by prompt reduction in immunodominant DSA and improvements in histologic and renal function. Early and late AMR differ immunologically and in response to PI therapy. Bortezomib-related toxicities in renal transplant recipients are similar to those observed in the multiple myeloma population. Critical Issues: Although preliminary evidence with PI therapy for AMR is encouraging, the evidence is limited. Larger, prospective, randomized controlled trials with long-term follow up are needed. Advancement in endpoints of clinical trial designs and rigorous clinical trials with more standardized adjunct therapies are also required to explore the risks and benefits of AMR treatment modalities. Future Directions: In the next few years, new PIs are likely to be introduced and new approaches would be developed for achieving synergy with PIs. The ultimate goal will be to develop a regimen that delivers reliable, rapid, complete, and durable elimination of DSA with an acceptable safety profile. Antioxid. Redox Signal. 21, 2401–2418.
Get full access to this article
View all access options for this article.
References
1.
AdamsJ. The proteasome: structure, function, and role in the cell. Cancer Treat Rev, 29: 3–9, 2003.
2.
AhmedT and SenzelL. The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection. J Clin Apher, 27: 173–177, 2012.
3.
AllenNH, DyerP, GeogheganT, HarrisK, LeeHA, and SlapakM. Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation, 35: 425–428, 1983.
4.
ArchdeaconP, ChanM, NeulandC, VelidedeogluE, MeyerJ, TracyL, Cavaille-CollM, BalaS, HernandezA, and AlbrechtR. Summary of FDA antibody-mediated rejection workshop. Am J Transplant, 11: 896–906, 2011.
5.
Ashton-ChessJ, MaiHL, JovanovicV, RenaudinK, FoucherY, GiralM, MoreauA, DugastE, MengelM, RacapéM, DangerR, UsalC, SmitH, GuilletM, GwinnerW, Le BerreL, DantalJ, SoulillouJP, and BrouardS. Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection. Kidney Int, 77: 880–890, 2010.
6.
BaslerM, DajeeM, MollC, GroettrupM, and KirkCJ. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol, 185: 634–641, 2010.
7.
BeckerYT, BeckerBN, PirschJD, and SollingerHW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant, 4: 996–1001, 2004.
8.
BianchiG, OlivaL, CascioP, PengoN, FontanaF, CerrutiF, OrsiA, PasqualettoE, MezghraniA, CalbiV, PalladiniG, GiulianiN, AndersonKC, SitiaR, and CenciS. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood, 113: 3040–3049, 2009.
9.
BöhmigGA, WahrmannM, RegeleH, ExnerM, RoblB, DerflerK, SolimanT, BauerP, MüllnerM, and DrumlW. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant, 7: 117–121, 2007.
10.
BonominiV, VangelistaA, FrascàGM, Di FeliceA, and Liviano D'ArcangeloG. Effects of plasmapheresis in renal transplant rejection. A controlled study. Trans Am Soc Artif Intern Organs, 31: 698–703, 1985.
11.
CalameKL. Plasma cells: finding new light at the end of B cell development. Nat Immunol, 2: 1103–1108, 2001.
12.
ClynesRA, TowersTL, PrestaLG, and RavetchJV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med, 6: 443–446, 2000.
13.
ColvinRB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol, 18: 1046–1056, 2007.
Dal PortoJM, HabermanAM, ShlomchikMJ, and KelsoeG. Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. J Immunol, 161: 5373–5381, 1998.
17.
EverlyMJ, EverlyJJ, ArendLJ, BraileyP, SusskindB, GovilA, RikeA, Roy-ChaudhuryP, MogilishettyG, AllowayRR, TevarA, and WoodleES. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant, 9: 1063–1071, 2009.
EverlyMJ, EverlyJJ, SusskindB, BraileyP, ArendLJ, AllowayRR, Roy-ChaudhuryP, GovilA, MogilishettyG, RikeAH, CardiM, WadihG, TevarA, and WoodleES. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation, 86: 1754–1761, 2008.
20.
EverlyMJ, TerasakiPI, HopfieldJ, TrivediHL, and KanekuH. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation, 90: 1493–1498, 2010.
21.
EverlyMJ, TerasakiPI, and TrivediHL. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation, 93: 572–577, 2012.
22.
EverlyJJ, WalshRC, AllowayRR, and WoodleES. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Trasplant, 14: 662–666, 2009.
23.
FlechnerSM, FaticaR, AskarM, StephanyBR, PoggioE, KooA, BanningS, Chiesa-VotteroA, and SrinivasT. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation, 90: 1486–1492, 2010.
24.
GloorJM, CosioFG, ReaDJ, WadeiHM, WintersJL, MooreSB, DeGoeySR, LagerDJ, GrandeJP, and StegallMD. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant, 6: 1841–1847, 2006.
25.
GomezAM, VrolixK, Martínez-MartínezP, MolenaarPC, PhernambucqM, van der EschE, DuimelH, VerheyenF, VollRE, ManzRA, De BaetsMH, and LosenM. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol, 186: 2503–2513, 2011.
26.
HaasM, MontgomeryRA, SegevDL, RahmanMH, RacusenLC, BagnascoSM, SimpkinsCE, WarrenDS, LepleyD, ZacharyAA, and KrausES. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant, 7: 576–585, 2007.
27.
HainzN, ThomasS, NeubertK, MeisterS, BenzK, RauhM, DanielC, WiesenerM, VollRE, and AmannK. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp Nephrol, 120: e47–e58, 2012.
28.
HalloranPF, de FreitasDG, EineckeG, FamulskiKS, HidalgoLG, MengeLM, ReeveJ, SellaresJ, and SisB. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant, 10: 2223–2230, 2010.
29.
JagannathS, BarlogieB, BerensonJ, SiegelD, IrwinD, RichardsonPG, NiesvizkyR, AlexanianR, LimentaniSA, AlsinaM, AdamsJ, KauffmanM, EsseltineDL, SchenkeinDP, and AndersonKC. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol, 127: 165–172, 2004.
30.
JordanSC, QuartelAW, CzerLS, AdmonD, ChenG, FishbeinMC, SchwiegerJ, SteinerRW, DavisC, and TyanDB. Posttransplant therapy using high-dose human immunoglobulin (intravenous gamaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation, 66: 800–805, 1998.
31.
JoudehA, SalibaKA, ToppingKA, and SisB. Pathologic basis of antibody-mediated organ transplant rejection: from pathogenesis to diagnosis. Curr Opin Organ Transplant, 18: 478–485, 2013.
32.
JungT and GruneT. The proteasome and the degradation of oxidized proteins: Part I—structure of proteasomes. Redox Biol, 1: 178–182, 2013.
33.
KalimKW, BaslerM, KirkCJ, and GroettrupM. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol, 189: 4182–4193, 2012.
34.
KamburovaEG, KoenenHJ, BoonL, HilbrandsLB, and JoostenI. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant, 12: 341–350, 2012.
35.
KaposztasZ, PodderH, MauiyyediS, IllohO, KermanR, ReyesM, PollardV, and KahanBD. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant, 23: 63–73, 2009.
36.
KazatchkineMD and KaveriSV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med, 345: 747–755, 2001.
37.
KihmLP, ZeierM, and MorathC. Emerging drugs for the treatment of transplant rejection. Expert Opin Emerg Drugs, 16: 683–695, 2011.
38.
KimR, EmiM, TanabeK, and MurakamiS. Role of the unfolded protein response in cell death. Apoptosis, 11: 5–13, 2006.
39.
KirubakaranMG, DisneyAP, NormanJ, PugsleyDJ, and MathewTH. A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation, 32: 164–165, 1981.
40.
KloetzelPM and OssendorpF. Proteasome and peptidase function in MHC-class I-mediated antigen presentation. Curr Opin Immunol, 16: 76–81, 2004.
41.
KuhnDJ, OrlowskiRZ, and BjorklundCC. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr Cancer Drug Targets, 11: 285–295, 2011.
42.
LedererSR, FriedrichN, BanasB, WelserG, AlbertED, and SitterT. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Clin Transplant, 19: 168–174, 2005.
43.
LeePC, ZhuL, TerasakiPI, and EverlyMJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation, 88: 568–574, 2009.
44.
LefaucheurC, NochyD, AndradeJ, VerineJ, GautreauC, CharronD, HillGS, GlotzD, and Suberbielle-BoisselC. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant, 9: 1099–1107, 2009.
45.
LoupyA, Suberbielle-BoisselC, HillGS, LefaucheurC, AnglicheauD, ZuberJ, MartinezF, ThervetE, MéjeanA, CharronD, Duong van HuyenJP, BrunevalP, LegendreC, and NochyD. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant, 9: 2561–2570, 2009.
46.
LucasJG, CoJP, NwaogwugwuUT, DosaniI, and SureshkumarKK. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother, 12: 579–592, 2011.
MarfoK, LuA, LingM, and AkalinE. Desensitization protocols and their outcome. Clin J Am Soc Nephrol, 6: 922–936, 2011.
49.
MauiyyediS and ColvinRB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens, 11: 609–618, 2002.
50.
McConkeyDJ and ZhuK. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat, 11: 164–179, 2008.
51.
MuchamuelT, BaslerM, AujayMA, SuzukiE, KalimKW, LauerC, SylvainC, RingER, ShieldsJ, JiangJ, ShwonekP, ParlatiF, DemoSD, BennettMK, KirkCJ, and GroettrupM. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med, 15: 781–787, 2009.
52.
MulleyWR, HudsonFJ, TaitBD, SkeneAM, DowlingJP, KerrPG, and KanellisJ. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation, 87: 286–289, 2009.
53.
NagayamaY, NakaharaM, ShimamuraM, HorieI, ArimaK, and AbiruN. Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto's thyroiditis, but not for Graves' hyperthyroidism, in mice. Clin Exp Immunol, 168: 268–273, 2012.
54.
NeubertK, MeisterS, MoserK, WeiselF, MasedaD, AmannK, WietheC, WinklerTH, KaldenJR, ManzRA, and VollRE. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med, 14: 748–755, 2008.
55.
NimmerjahnF and RavetchJV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol, 26: 513–533, 2008.
56.
OrlowskiRZ, NaglerA, SonneveldP, BladéJ, HajekR, SpencerA, San MiguelJ, RobakT, DmoszynskaA, HorvathN, SpickaI, SutherlandHJ, SuvorovAN, ZhuangSH, ParekhT, XiuL, YuanZ, RackoffW, and HarousseauJL. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol, 25: 3892–3901, 2007.
57.
PascualM, SaidmanS, Tolkoff-RubinN, WilliamsWW, MauiyyediS, DuanJM, FarrellML, ColvinRB, CosimiAB, and DelmonicoFL. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation, 66: 1460–1464, 1998.
58.
PerryDK, BurnsJM, PollingerHS, AmiotBP, GloorJM, GoresGJ, and StegallMD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant, 9: 201–209, 2009.
59.
PottsBC, AlbitarMX, AndersonKC, BaritakiS, BerkersC, BonavidaB, ChandraJ, ChauhanD, CusackJCJr, FenicalW, GhobrialIM, GrollM, JensenPR, LamKS, LloydGK, McBrideW, McConkeyDJ, MillerCP, NeuteboomST, OkiY, OvaaH, PajonkF, RichardsonPG, RoccaroAM, SlossCM, SpearMA, ValashiE, YounesA, and PalladinoMA. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets, 11: 254–284, 2011.
60.
PuttarajappaC, ShapiroR, and TanHP. Antibody-mediated rejection in kidney transplantation: a review. J Transplant, 2012: 193724, 2012.
61.
QinJZ, ZiffraJ, StennettL, BodnerB, BonishBK, ChaturvediV, BennettF, PollockPM, TrentJM, HendrixMJ, RizzoP, MieleL, and NickoloffBJ. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res, 65: 6282–6293, 2005.
62.
RadbruchA, MuehlinghausG, LugerEO, InamineA, SmithKG, DörnerT, and HiepeF. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol, 6: 741–750, 2006.
63.
RamosEJ, PollingerHS, StegallMD, GloorJM, DoganA, and GrandeJP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant, 7: 402–407, 2007.
64.
RichardsonPG, SonneveldP, SchusterMW, IrwinD, StadtmauerEA, FaconT, HarousseauJL, Ben-YehudaD, LonialS, GoldschmidtH, ReeceD, San-MiguelJF, BladéJ, BoccadoroM, CavenaghJ, DaltonWS, BoralAL, EsseltineDL, PorterJB, SchenkeinD, and AndersonKC. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 352: 2487–2498, 2005.
65.
RobertsDM, JianSH, and ChadbanSJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients–a systematic review. Transplantation, 94: 775–783, 2012.
66.
RochaPN, ButterlyDW, GreenbergA, ReddanDN, Tuttle-NewhallJ, CollinsBH, KuoPC, ReinsmoenN, FieldsT, HowellDN, and SmithSR. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation, 75: 1490–1495, 2003.
67.
SadakaB, AllowayRR, and WoodleES. Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opin Invest Drugs, 20: 1535–1542, 2011.
68.
Sberro-SoussanR, ZuberJ, Suberbielle-BoisselC, CandonS, MartinezF, SnanoudjR, RabantM, PalletN, NochyD, AnglicheauD, LeruezM, LoupyA, ThervetE, HermineO, and LegendreC. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant, 10: 681–686, 2010.
69.
Sberro-SoussanR, ZuberlJ, Suberbielle-BoisselC, and LegendreC. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment. Clin Transpl, 2010: 409–414, 2010.
70.
SchmidtN, AllowayRR, WalshRC, SadakaB, ShieldsAR, GirnitaAL, HansemanDJ, and WoodleES. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation, 94: 352–361, 2012.
71.
SinghN, PirschJ, and SamaniegoM. Antibody mediated rejection: treatment alternatives and outcome. Transplant Rev (Orlando), 23: 34–46, 2009.
StegallMD, DeanPG, and GloorJ. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant, 9: 998–1005, 2009.
75.
SureshkumarKK, HussainSM, CarpenterBJ, SandroniSE, and MarcusRJ. Antibody-mediated rejection following renal transplantation. Expert Opin Pharmacother, 8: 913–921, 2007.
76.
TakemotoSK, ZeeviA, FengS, ColvinRB, JordanS, KobashigawaJ, Kupiec-WeglinskiJ, MatasA, MontgomeryRA, NickersonP, PlattJL, RabbH, ThistlethwaiteR, TyanD, and DelmonicoFL. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant, 4: 1033–1041, 2004.
77.
TrivediHL, TerasakiPI, FerozA, EverlyMJ, VanikarAV, ShankarV, TrivediVB, KanekuH, IdicaAK, ModiPR, KhemchandaniSI, and DaveSD. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation, 87: 1555–1561, 2009.
78.
TydenG, KumlienG, and EfvergrenM. Present techniques for antibody removal. Transplantation, 84: S27–S29, 2007.
79.
TzvetanovI, SpaggiariM, JosephJ, JeonH, ThielkeJ, OberholzerJ, and BenedettiE. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature. Transplant Proc, 44: 2971–2975, 2012.
80.
ValenzuelaNM and ReedEF. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. Methods Mol Biol, 1034: 41–70, 2013.
81.
VaniJ, ElluruS, NegiVS, Lacroix-DesmazesS, KazatchkineMD, BayryJ, and KaveriSV. Role of natural antibodies in immune homeostatsis: IVIg perspective. Autoimmun Rev, 7: 440–444, 2008.
WaiserJ, BuddeK, SchützM, LiefeldtL, RudolphB, SchönemannC, NeumayerHH, and LachmannN. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant, 27: 1246–1251, 2012.
84.
WalshRC, BraileyP, GirnitaA, AllowayRR, ShieldsAR, WallGE, SadakaBH, CardiM, TevarA, GovilA, MogilishettyG, Roy-ChaudhuryP, and WoodleES. Early and late acute antibody-mediated rejection differs immunologically and in response to proteasome inhibition. Transplantation, 91: 1218–1226, 2011.
WeinerGJ. Rituximab: mechanism of action. Semin Hematol, 47: 115–123, 2010.
87.
WoodleES, WalshRC, AllowayRR, GirnitaA, and BraileyP. Proteasome inhibitor therapy for antibody-mediated rejection. Pediatr Transplant, 15: 548–556, 2011.
88.
WuJ. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant, 2: 904–912, 2002.
89.
ZarkhinV, LiL, KambhamN, SigdelT, SalvatierraO, and SarwalMM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant, 8: 2607–2617, 2008.
